Phase II Study of Gemcitabine and CPT-11 (Irinotecan) in Unresectable or Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Gemcitabine (Primary) ; Irinotecan (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 27 Apr 2012 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Aug 2007 Status changed from recuiting to in progress.